JP2015503554A5 - - Google Patents

Download PDF

Info

Publication number
JP2015503554A5
JP2015503554A5 JP2014550024A JP2014550024A JP2015503554A5 JP 2015503554 A5 JP2015503554 A5 JP 2015503554A5 JP 2014550024 A JP2014550024 A JP 2014550024A JP 2014550024 A JP2014550024 A JP 2014550024A JP 2015503554 A5 JP2015503554 A5 JP 2015503554A5
Authority
JP
Japan
Prior art keywords
glp
group
derivative
immunoglobulin
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014550024A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503554A (ja
JP6131490B2 (ja
Filing date
Publication date
Priority claimed from KR1020110147684A external-priority patent/KR101895047B1/ko
Application filed filed Critical
Publication of JP2015503554A publication Critical patent/JP2015503554A/ja
Publication of JP2015503554A5 publication Critical patent/JP2015503554A5/ja
Application granted granted Critical
Publication of JP6131490B2 publication Critical patent/JP6131490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014550024A 2011-12-30 2012-12-28 免疫グロブリンフラグメントを用いた部位特異的glp−2薬物結合体 Active JP6131490B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020110147684A KR101895047B1 (ko) 2011-12-30 2011-12-30 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
KR10-2011-0147684 2011-12-30
PCT/KR2012/011748 WO2013100704A1 (en) 2011-12-30 2012-12-28 A site-specific glp-2 conjugate using an immunoglobulin fragment

Publications (3)

Publication Number Publication Date
JP2015503554A JP2015503554A (ja) 2015-02-02
JP2015503554A5 true JP2015503554A5 (cg-RX-API-DMAC7.html) 2016-01-28
JP6131490B2 JP6131490B2 (ja) 2017-05-24

Family

ID=48698036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014550024A Active JP6131490B2 (ja) 2011-12-30 2012-12-28 免疫グロブリンフラグメントを用いた部位特異的glp−2薬物結合体

Country Status (9)

Country Link
US (1) US9504757B2 (cg-RX-API-DMAC7.html)
EP (1) EP2797621B1 (cg-RX-API-DMAC7.html)
JP (1) JP6131490B2 (cg-RX-API-DMAC7.html)
KR (1) KR101895047B1 (cg-RX-API-DMAC7.html)
CN (2) CN109810198B (cg-RX-API-DMAC7.html)
AR (1) AR089506A1 (cg-RX-API-DMAC7.html)
ES (1) ES2725805T3 (cg-RX-API-DMAC7.html)
TW (1) TWI666219B (cg-RX-API-DMAC7.html)
WO (1) WO2013100704A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
EP3046586B1 (en) * 2013-09-19 2021-07-07 The Regents of The University of California Methods of treatment using bis-polymer lipid-peptide conjugates and nanoparticles thereof
US9994616B2 (en) 2013-10-15 2018-06-12 The University Of Tokyo c-Met protein agonist
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
EP4303228B1 (en) 2016-07-11 2026-05-27 OPKO Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
WO2018157131A1 (en) 2017-02-27 2018-08-30 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
KR102174436B1 (ko) * 2017-08-17 2020-11-04 주식회사 엘지화학 불용성 안료 화합물의 정성분석방법
AU2018321841A1 (en) * 2017-08-22 2020-02-20 Shire-Nps Pharmaceuticals, Inc. GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
AR113258A1 (es) * 2017-09-28 2020-03-11 Hanmi Pharm Ind Co Ltd Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)
CN111629745A (zh) * 2017-11-06 2020-09-04 夏尔-Nps医药品有限公司 用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies)
WO2020086741A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
US20200254065A1 (en) * 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
WO2020198604A1 (en) * 2019-03-28 2020-10-01 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of treating and preventing systemic complications of acute illness
EP4069726A4 (en) 2019-12-04 2024-03-20 The Scripps Research Institute GLP2 RECEPTOR AGONISTS AND METHOD OF USE
EP4082561A4 (en) * 2019-12-24 2024-02-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof
CN115697375A (zh) * 2020-04-03 2023-02-03 韩美药品株式会社 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
IL298298A (en) * 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of glp–2
CN111560062A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Elisiglutide的制备方法
WO2022159555A1 (en) * 2021-01-20 2022-07-28 The Trustees Of Columbia University In The City Of New York Methods for treating graft-versus-host disease using glp-2 agonists and analogues thereof
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
CN1705681A (zh) * 2002-10-14 2005-12-07 诺沃挪第克公司 Glp-2化合物、制剂及其用途
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US7829307B2 (en) 2003-11-21 2010-11-09 Nps Pharmaceuticals, Inc. Production of glucagon-like peptide 2
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
AU2006321743A1 (en) 2005-10-24 2007-06-14 Centocor, Inc. GLP-2 mimetibodies, polypeptides, compositions, methods and uses
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP5759976B2 (ja) * 2009-03-20 2015-08-05 ハンミ・サイエンス・カンパニー・リミテッド 位置特異的な生理活性ポリペプチド結合体の調製方法
JP2012521197A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
KR101746686B1 (ko) 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체

Similar Documents

Publication Publication Date Title
JP2015510880A5 (cg-RX-API-DMAC7.html)
AU2018203729B2 (en) Composition For Treating Hyperlipidemia Comprising Oxyntomodulin Derivative
RU2012146663A (ru) Конъюгат инсулина с применением фрагмента иммуноглобулина
KR102385120B1 (ko) 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
RU2009129953A (ru) Инсулинотропный комплекс, в котором использован фрагмент иммуноглобулина
RU2015138536A (ru) Новый аналог инсулина и его применение
RU2015133462A (ru) Сайт-специфичный конъюгат инсулина
RU2312868C2 (ru) Физиологически активный полипептидный конъюгат, обладающий пролонгированным периодом полувыведения in vivo
JP2020534840A5 (cg-RX-API-DMAC7.html)
RU2014108725A (ru) Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа
RU2016147505A (ru) Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
RU2014133615A (ru) Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой болезни печени
EP2570137A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
IL263616B1 (en) Antibody adjuvant conjugates
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
JP2019524675A5 (cg-RX-API-DMAC7.html)
WO2004113387A3 (en) Tumour necrosis factor receptor molecules with reduced immunogenicity
IL273528B2 (en) Long-acting conjugates of glp-2 derivatives
JP2013533875A5 (cg-RX-API-DMAC7.html)
CN107029242A (zh) 抗体药物复合物及其制造方法
WO2016067021A1 (en) Materials and methods relating to linkers for use in protein drug conjugates
TH1801008130A (th) อนุพันธ์กลูคากอน, คอนจูเกตของสิ่งนั้น, องค์ประกอบซึ่งประกอบรวมด้วยสิ่งเดียวกัน, และการใช้ในการรักษาโรคของสิ่งดังกล่าว
NZ750267B2 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
NZ750267A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
NZ764889B2 (en) Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist